Comparison of PD and bile duct resection for middle bile duct cancer (Is additional-PD after bile duct segmental resection sufficient to surgical treatment for middle bile duct cancer?) Japan-Korea Collaborative Research of Hepato-Biliary-Pancreatic Surgery Biliary part

Comparison of PD and bile duct resection for middle bile duct cancer (Is additional-PD after bile duct segmental resection sufficient to surgical treatment for middle bile duct cancer?) Japan-Korea Collaborative Research of Hepato-Biliary-Pancreatic Surgery Biliary part - Comparison of PD and bile duct resection for middle bile duct cancer (Is additional-PD after bile duct segmental resection sufficient to surgical treatment for middle bile duct cancer?) Japan-Korea Collaborative Research

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017914

Enrollment

3600

Registered

2015-07-01

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Middle bile duct cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Middle bile duct cancer (definition of middle bile duct cancer is described above) -Resected between 2001-2010 -Clinically T1, T2, T3 (without invasion to liver parenchyma by preoperative diagnostic imaging and intraoperative macroscopic findings) in TNM 7th classification (ICD-O C24.0) (cT1/2/3 but pT4 cancer should be included) -M0 -Surgical strategies are defined as bile duct segmental resection (BDSR), pancreaticoduodenectomy including PD, PpPD and SSPPD (PD) and additional PD (AdPD).

Exclusion criteria

Exclusion criteria: -Bismuth type I hilar cholangiocarcinoma -cT4 cancer (With invasion to liver parenchyma by preoperative diagnostic imaging and intraoperative macroscopic findings) (cT1/2/3 but pT4 cancer should not be excluded) -M1 desease -Preoperative chemotherapy and/or radiation -With hepatectomy (additional hepatectomy after BDSR or PD is excluded in this study) -Patient with other cancer within 5-year

Design outcomes

Primary

Measure	Time frame
desease free survival	—

Secondary

Measure	Time frame
Overall survival R0 resection rate Morbidity rate Mortality rate Recurrence rate Site of Recurrence	—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactHiroki Hayashi

Tohoku University Graduate School of Medicine Gastroenterology

hiroki@surg1.med.tohoku.ac.jp022-717-7205

Outcome results